Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia.
A study is described of effects of a nootropic drug on chronic schizophrenia. The nootropic drugs act on the central nervous system with the cerebral cortex as their target. Chronic schizophrenic patients on the drug showed improvement in object naming and in tests where the patient was required to indicate the number of times he had been tapped. Improvements were also noted in learning and memory tasks. In dichotic listening the patients showed a reduction in the amount of incorrect verbal responses produced. There were no improvements in symptom rating or social behaviour rating. These results suggest some cognitive improvement but little if any change in the disease state of the patient.
D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004007:Dichotic Listening Tests; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D010889:Piracetam / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D011760:Pyrrolidinones; D010889:Piracetam